{"url_path":"/sec/rmtg/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1760026/0001213900-26-066838-index.html","accession_number":"0001213900-26-066838","cik":"0001760026","ticker":"RMTG","issuer_name":"Regenerative Medical Technology Group Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1760026/0001213900-26-066838-index.html","primary_entity_key":"0001760026","primary_entity_name":"Regenerative Medical Technology Group Inc."},"word_count":413,"has_tables":true,"body_markdown":"** **\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n☒ **QUARTERLY REPORT PURSUANT TO SECTION 13\nOR 15(d) OF THE SECURITIES** **EXCHANGE ACT OF 1934**\n\n \n\nFor the quarterly period ended:** March 31,\n2026**\n\n \n\nor\n\n \n\n**☐ TRANSITION REPORT PURSUANT TO SECTION 13\nOR 15(d) OF THE SECURITIES** **EXCHANGE ACT OF 1934**\n\n \n\nFor the transition period from __________ to __________\n\n \n\nCommission File Number**: 000-56010**\n\n \n\n**Regenerative Medical Technology Group Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Nevada**   **88-0492191**\n\n(State or other jurisdiction\n\nof incorporation)   (IRS Employer\n\nIdentification No.)\n\n \n\n**433 Plaza Real Suite 275**\n\n**Boca Raton, Florida 33432**\n\n(Address of principal executive offices)\n\n \n\n**(800) 956-3935**\n\n(Registrant’s telephone number, including\narea code)\n\n \n\n \n\n(Former name, former address and former fiscal\nyear end, if changed since last report)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\nNone\n \nNone\n \nNone\n\n \n\nIndicate by check mark whether the registrant\n(1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months,\nand (2) has been subject to such filing requirements for the past 90 days.  Yes ☒   No ☐\n\n \n\nIndicate by check mark whether the registrant\nhas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405\nof this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). \nYes  ☒   No ☐\n\n \n\nIndicate by check mark whether the registrant\nis large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See\ndefinition of “large accelerated filer,” accelerated filer” “smaller reporting company,” and “emerging\ngrowth company” in Rule 12b-2 of the Exchange Act:\n\n \n\nLarge accelerated filer  ☐  Accelerated filer  ☐\n\nNon-accelerated filer  ☒ Smaller Reporting Company  ☒\n\nEmerging growth company  ☐     \n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant\nis a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒\n\n \n\nAs of June 09, 2026, there were 13,138,968 shares outstanding of the\nregistrant’s common stock.\n\n \n\n \n\n \n\n \n\n \n\n**Regenerative Medical Technology Group Inc.**\n\n** **\n\n**TABLE OF CONTENTS**\n\n** **\n\n \n \n**Page No.**\n\n[**PART I.\nFINANCIAL INFORMATION**](#a_001)"}